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ABSTRACT
Background    Gastric cancer patients with peritoneal 
metastasis have an extremely poor prognosis. The aim of 
the current study was to clarify the predictive factors of 
a better outcome in gastric cancer patients with peritone-
al metastasis. 
Methods    We analyzed the records of 2262 gastric 
adenocarcinoma patients who underwent gastrectomies 
at our institution between January 1980 and December 
2010.
Results    The 5-year survival rates for advanced gastric 
cancer patients with P1 (n = 43), P2 (n = 56), and P3 (n 
= 36) metastasis were 16.3%, 0%, and 0%, respectively. 
The prognosis of P1 gastric cancer patients was signifi-
cantly better than that of either P2 (P = 0.0003) or P3 
patients (P < 0.0001). A multivariate analysis identified 
gross appearance and curability as independent prognos-
tic indicators in P1 gastric cancer patients. In fact, the 
prognosis was good for patients in whom an R0/1 resec-
tion had been performed and with tumors having a gross 
appearance of other than type 4, with a 40% 5-year sur-
vival rate and a 29-month median survival time.
Conclusion    Our data indicated a good prognosis for 
P1 patients in whom an R0/1 resection could be per-
formed and with tumors having a gross appearance of 
other than type 4. Therefore, radical surgery and ade-
quate adjuvant chemotherapy should be performed in 
these patients. 
Key words    gastric carcinoma; peritoneal metastasis; 
prognosis; recurrence
Gastric cancer disseminates by hematogenous and lym-
phatic routes and by direct implantation on peritoneal 
surfaces. Peritoneal dissemination is the most frequent 
pattern of metastasis and recurrence in patients with gas-
tric cancer.1–3 Concomitant peritoneal metastases are fre-
quently observed at the time of diagnosis in patients with 
advanced gastric cancer. The prognosis for patients with 
peritoneal metastasis is extremely poor, with a median 
survival of about 6 months.4, 5 Therefore, systemic che-
motherapy is generally administered to these patients. 
Although the prognosis for gastric cancer patients with 
peritoneal dissemination has been gradually improving 
because of improvements in systemic chemotherapy, it is 
not yet satisfactory. Because of the poor prognosis, sur-
gery is not typically a treatment option for these patients 
unless there is obstruction or bleeding. However, some 
previous studies have documented positive effects of 
palliative gastric cancer resection on survival in gastric 
cancer patients with peritoneal carcinomatosis.6–12 These 
results indicate that there might be patients who receive 
survival benefit by gastrectomy in gastric cancer patients 
with peritoneal metastasis. Therefore, it is extremely im-
portant to identify the patients with peritoneal metastasis 
whose prognosis can be improved by gastrectomy. How-
ever, there is little information on this regard thus far. 
Therefore, the aim of the current study was to clarify the 
predictive factors of a better prognosis after gastrectomy 
in gastric cancer patients with peritoneal carcinomatosis
MATERIALS AND METHODS
Patients 
We examined the records of 2262 consecutive gastric 
adenocarcinoma patients who underwent gastrectomies 
at our institution between January 1980 and December 
2010. The data were collected retrospectively. Patients’ 
ages ranged between 20 and 100 years with an average 
of 62.0 years; 1447 patients were male and 815 were 
female. Clinicopathological findings were generally 
determined according to the 14th edition of the Japanese 
Classification of Gastric Carcinoma, except for the clas-
sification of peritoneal metastasis and the definition of 
a curative operation.13 The diagnosis of peritoneal dis-
semination was based on the operative and histological 
identification of peritoneal nodules at the time of the 
operation. The classification of peritoneal metastasis was 
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determined according to the 12th edition of the Japanese 
Classifi cation of Gastric Carcinoma: P0, no dissemina-
tion; P1, disseminating metastasis to the adjacent peri-
toneum of the stomach; P2, a few scattered metastases 
to the distant peritoneum; and P3, numerous metastases 
to the distant peritoneum.14 Institutional review board 
Table 1. Clinicopathologic characteristics according to peritoneal metastasis status
Variables P1 (n = 43) P2 (n = 56) P3 (n = 36)
Gross appearance
Type 4 15 (34.9%) 26 (46.4%) 16 (44.4%)
Except type 4 28 (65.1%) 30 (53.6%) 20 (55.6%)
Tumor size 10.6 ± 5.2 11.1 ± 4.8 10.7 ± 4.4 
Serosal invasion
Absent 5 (11.6%) 2 (3.6%) 3 (8.3%) 
Present 38 (88.4%) 54 (96.4%) 33 (91.7%)
Number of lymph node metastasis 15.3 ± 16.8  17.7 ± 17.7 15.8 ± 12.3 
Lymphatic vessel invasion
Absent 4 (9.3%) 9 (16.1%) 3 (8.3%)
Present 39 (90.7%) 47 (83.9%) 33 (91.7%)
Blood vessel invasion
Absent 8 (18.6%)  18 (32.1%) 11 (30.6%)
Present 35 (81.4%) 38 (67.9%) 25 (69.4%)
Liver metastasis
Absent 37 (86.0%) 50 (89.3%) 32 (88.9%)
Present 6 (14.0%) 6 (10.7%) 4 (11.1%)
Curability
Curative 25 (58.1%)* 4 (7.1%)** 0 (0%)**
Non-curative 18 (41.9%) 52 (92.9%) 36 (100%)
*versus ** P < 0.0001
P1 (n = 43; 16.3%)
P2 (n = 56; 0%)
P3 (n = 36; 0%)
P1 vs. P2  P = 0.0003
P1 vs. P3  P < 0.0001
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Saito et al. Figure 1
Fig. 1. Survival curves for advanced gastric cancer patients with 
peritoneal metastasis. The 5-year survival rates for advanced gas-
tric cancer patients with P1, P2, and P3 metastasis were 16.3%, 
0%, and 0%, respectively. The prognosis for P1 gastric cancer 
patients was signifi cantly better than the prognosis for either P2 or 
P3 gastric cancer patients.
approval was obtained on July 2017 (1607A051), and the 
informed consent requirement was waived for this study.
Statistical analysis 
Survival rates were constructed using the Kaplan–Meier 
method, and differences between survival curves were 
examined with the log rank test. Multivariate analysis 
was performed using the Cox proportional hazards 
model and a stepwise procedure. The accepted level of 
signifi cance was P < 0.05. A StatView software package 
(Abacus Concepts, Berkeley, CA) was used for all statis-
tical analyses. 
RESULTS
Among the study population, 43, 56, and 36 patients 
underwent gastrectomy for P1, P2, and P3 gastric can-
cer, respectively. Table 1 shows the clinicopathologic 
fi ndings according to peritoneal metastasis status. Cu-
rative operations were more frequently performed in P1 
patients than in P2 or P3 patients; the differences in cu-
rative resection rates between P1 and P2 or P3 patients 
were statistically signifi cant. No signifi cant differences 
were observed in the other clinicopathologic fi ndings.
 The 5-year survival rates for advanced gastric can-
cer patients with P1, P2, and P3 metastasis were 16.3%, 
0%, and 0%, respectively. The prognosis for P1 gastric 
cancer patients was signifi cantly better than the progno-
sis for either P2 or P3 gastric cancer patients (Fig. 1). 
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Table 2. Multivariate analysis using the Cox propor-
tional hazards model and a stepwise procedure in P1 
gastric cancer patients 
P Hazard 95% CI
Curability 
(curative vs. non-curative) 0.0006 0.289 0.142–0.589
Gross appearance 
(Type 4 vs. others) 0.0357 2.104 1.051–4.212
CI, confi dence interval.
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Group A (n = 15; 40%)
Group B (n = 10; 10%)
Group C (n = 18; 0%)
Group A vs. Group B  P = 0.045
Group A vs. Group C  P = 0.0003
Saito et al. Figure 2
Fig. 2. Group A, patients in whom an R0/1 resection had been per-
formed and with tumors having a gross appearance of other than 
type 4; Group B, patients in whom an R0/1 resection had been per-
formed and with type 4 tumors; and Group C, patients in whom 
an R0/1 resection had not been performed. The 5-year survival 
rates and median survival times were 40% (29 months), 10% (11 
months), and 0% (8 months) in groups A, B, and C, respectively. 
The prognosis for group A was signifi cantly better than the prog-
nosis for group B (P = 0.045) and group C (P = 0.0003).
 Among 43 P1 patients, 37 patients (86.0%) under-
went chemotherapy, while the remainder did not. It 
is likely that chemotherapy affect the prognosis of P1 
patients. Since this study is retrospective study, vari-
ous kind of chemotherapy was used. In brief, tegafur 
(FT-207, Taiho, Tokyo, Japan) was used in 14 patients 
and uracil-tegafur (UFT, Taiho) in 10 patients. These 
patients received either 600 to 800 mg of FT twice or 
200 to 400 mg of UFT twice or three times daily orally. 
Tegafur-gimeracil-oteracil (S-1, Taiho) was used in 4 pa-
tients. In principle, 80 mg of oral S-1 per square meter of 
body-surface area per day was given for 4 weeks and no 
chemotherapy was given for the following 2 weeks. This 
6-week cycle was repeated. Mitomycin C (MMC) was 
used in 26 patients as follows: i) intraperitoneal admin-
istration at a dose of 8 mg to 10 mg after surgical resec-
tion in 9 patients, ii) intravenous administration at a dose 
of 8 mg to 30 mg after surgical resection and / or on 
postoperative days in 26 patients. Four patients received 
a continuous infusion of ﬂ uorouracil with CDDP. Con-
tinuous hyperthermic peritoneal perfusion (CHPP) with 
physiologic saline that contained either 10 µg/mL MMC 
or 125 to 150 mg CDDP was used in 3 patients. Multi-
variate analysis identifi ed gross appearance and curabil-
ity, but not chemotherapy, as independent prognostic in-
dicators in P1 gastric cancer patients (Table 2). Based on 
the results of the multivariate analysis, P1 gastric cancer 
patients were classifi ed in 3 groups as follows: group A, 
patients in whom an R0/1 resection had been performed 
and with tumors having a gross appearance of other than 
type 4; group B, patients in whom an R0/1 resection had 
been performed and with a type 4 tumor; and group C, 
patients in whom an R0/1 resection had not been per-
formed. The 5-year survival rates and median survival 
times (MSTs) were 40% (29 months), 10% (11 months), 
and 0% (8 months) in groups A, B, and C, respectively. 
The prognosis for group A was signifi cantly better than 
the prognosis for group B (P = 0.045) and group C (P = 
0.0003) (Fig. 2). 
 In P2/3 patients, multivariate analysis identifi ed the 
presence of other incurable factors to be an independent 
prognostic indicator. The MSTs for patients with and 
without other incurable factors were 5 months and 8 
months, respectively, and this difference was statistically 
signifi cant (P = 0.0035).
DISCUSSION
Gastric cancer is one of the most common malignancies. 
Although the prognosis for patients with gastric carci-
noma has improved because of the availability of diag-
nostic techniques and better intraoperative and postop-
erative care, death from gastric cancer still ranks second 
among all cancer deaths worldwide.15 The most com-
mon site of gastric cancer metastasis is the peritoneum. 
Peritoneal carcinomatosis is a common manifestation 
of digestive tract cancer and is generally regarded as a 
terminal condition with a short median survival. In fact, 
the prognosis for P2 or P3 patients is extremely poor; we 
found no 5-year survivors in the current study. Because 
of this extremely poor prognosis, systemic chemother-
apy is the main therapeutic option for gastric cancer 
patients with peritoneal metastasis. The issue of whether 
or not gastrectomy achieves a survival benefi t for those 
patients is controversial. In the current study, we identi-
fi ed a 5-year survival rate of 16.5% in P1 gastric cancer 
patients. Although this survival rate was not favorable, it 
is true that systemic chemotherapy alone could not have 
achieved this survival rate. Thus, it appears that there 
is a certain population in which gastrectomy provided 
a significant survival benefit compared with systemic 
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chemotherapy alone in P1 gastric cancer patients. From 
clinical point of view, it is extremely important to iden-
tify that population. However, there is little information 
on this regard thus far. Therefore, we then applied a 
multivariate analysis to determine predictive factors of 
improved survival after gastrectomy in gastric cancer 
patients with P1 peritoneal metastasis and found gross 
appearance and curability to be independent prognostic 
indicators. In fact, these two factors were very effective 
in predicting the prognosis of P1 gastric cancer patients, 
and the 5-year survival rate and MST were 40% and 29 
months, respectively, in patients in whom an R0/1 resec-
tion had been performed and with tumors having a gross 
appearance of other than type 4. Hioki et al. reported 
that gastric cancer patients with P1/P2 carcinomatosis 
and well/moderately differentiated tumors were likely to 
have an improved survival after gastrectomy, with a me-
dian survival of 25 months, a 3-year survival of 45.5%, 
and a 5-year survival of 27.3%. Therefore, these authors 
emphasized that patients with a good performance 
status and P1/P2 carcinomatosis should be considered 
appropriate surgical candidates instead of treating them 
with palliative systemic chemotherapy alone.16 It is well 
known that predominant histology of type 4 tumor was 
signet-ring cell carcinoma and poorly differentiated 
carcinoma. Therefore, our results are almost consistent 
with their results. Therefore, surgery should primarily 
be considered in patients in whom an R0/1 resection can 
be performed and with tumors having a gross appear-
ance of other than type 4. Because the prognosis was 
extremely poor for the rest of the P1 patients, chemo-
therapy should be the primary treatment considered in 
these patients. On the other hand, the presence of other 
incurable factors was an independent prognostic indica-
tor in P2/3 gastric cancer patients in the current study. 
However, even in P2/3 patients, the MST was 8 months 
for patients without other incurable factors. Therefore, 
chemotherapy should also be considered in P2/P3 pa-
tients.
 Even when an R0 resection can be achieved in 
patients with peritoneal metastasis, there is a high pos-
sibility of residual micrometastases, which can induce 
recurrence postoperatively. Because chemotherapy can 
eliminate micrometastases that surgery cannot, chemo-
therapy plays an extremely important role in improving 
the prognosis of gastric cancer patients with peritoneal 
metastasis. A recent study showed perioperative chemo-
therapy to significantly improve progression-free and 
overall survival in patients with operable gastric and 
lower esophageal adenocarcinomas.17 Preoperative che-
motherapy has the potential benefit of eliminating mi-
crometastases prior to surgery. Therefore, preoperative 
chemotherapy might be useful in improving the progno-
sis for patients with peritoneal metastasis in whom an R0 
resection can be performed. Moreover, intraperitoneal 
chemotherapy using paclitaxel in combination with gen-
eral chemotherapy was recently shown to significantly 
improve survival in ovarian cancer patients with perito-
neal metastasis.18 This therapy might also be effective in 
the previously mentioned patient population.
 Accurate clinical staging is extremely important 
in formulating the treatment strategy for patients with 
peritoneal metastasis. Conventional imaging techniques 
often underestimate the extent of the intra-abdominal 
spread of advanced gastric cancer. Clinical staging can 
be improved by laparoscopy, as this modality enables 
the identification of intra-abdominal tumor deposits 
on peritoneal surfaces, which may not be detected by 
noninvasive preoperative imaging. Therefore, staging 
laparoscopies should be performed in advanced gastric 
cancer patients with possible peritoneal metastasis to 
better guide treatment strategies.
 There are a few limitations in the present study. 
First, because this was a retrospective study covering a 
long period, there is some bias. Especially, chemother-
apy regimens underwent significant changes during the 
course of the study and patients received a variety of 
chemotherapy regimens. This is likely to have affected 
the study results although chemotherapy was not an in-
dependent prognostic factor. Second, the number of pa-
tients included in the current study was small; therefore 
a large-scale, prospective, randomized, controlled trial is 
needed to confirm the results.
 In conclusion, our data indicated a good progno-
sis for P1 patients in whom an R0/1 resection could be 
performed and with tumors having a gross appearance 
of other than type 4. Therefore, radical surgery and ad-
equate adjuvant chemotherapy should be performed in 
patients meeting these criteria.
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